How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

123 results for

Asthma-Related Death Risk Factors

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Asthma-Related Death Risk Factors

Death Risk Factors Asthma-Related Death Risk Factors Aka: Asthma-Related Death Risk Factors , Fatal Asthma Attack Risk Factors II. Precaution One third of fatal attacks occur in children with only history Emphasize and at each visit One or more risk factors should prompt early and aggressive evaluation for s Have low threshold for hospitalization of Consider intensive care unit admission III. Risk Factors: Asthma History predisposing to Asthma-related death Patient unable to sense or distinguish (...) Asthma-Related Death Risk Factors Asthma-Related Death Risk Factors Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Asthma-Related

2018 FP Notebook

2. Asthma-related deaths Full Text available with Trip Pro

Asthma-related deaths Despite major advances in the treatment of asthma and the development of several asthma guidelines, people still die of asthma currently. According to WHO estimates, approximately 250,000 people die prematurely each year from asthma. Trends of asthma mortality rates vary very widely across countries, age and ethnic groups. Several risk factors have been associated with asthma mortality, including a history of near-fatal asthma requiring intubation and mechanical (...) . Inadequate education of patients on recognising risk and the appropriate action needed when asthma control is poor, deficiencies in the accuracy and timing of asthma diagnosis, inadequate classification of severity and treatment, seem to play a part in the majority of asthma deaths. Improvements in management, epitomized by the use of guided self-management systems of care may be the key goals in reducing asthma mortality worldwide.

2016 Multidisciplinary respiratory medicine

3. Asthma-Related Death Risk Factors

Death Risk Factors Asthma-Related Death Risk Factors Aka: Asthma-Related Death Risk Factors , Fatal Asthma Attack Risk Factors II. Precaution One third of fatal attacks occur in children with only history Emphasize and at each visit One or more risk factors should prompt early and aggressive evaluation for s Have low threshold for hospitalization of Consider intensive care unit admission III. Risk Factors: Asthma History predisposing to Asthma-related death Patient unable to sense or distinguish (...) Asthma-Related Death Risk Factors Asthma-Related Death Risk Factors Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Asthma-Related

2015 FP Notebook

4. Overuse of short-acting beta2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme Full Text available with Trip Pro

short-acting β 2 -agonist (SABA... FIGURE 4 Kaplan–Meier plot of overall survival by baseline short-acting β 2 -agonist (SABA) use. FIGURE 5 5 Association between baseline short-acting β... FIGURE 5 13 Association between baseline short-acting β 2 -agonist (SABA) use and risk of mortality... FIGURE 5 Association between baseline short-acting β 2 -agonist (SABA) use and risk of mortality. a) Overall mortality; b) asthma-related mortality; c) respiratory-related mortality. Adjusted for treatment step (...) asthma control and adverse health outcomes. Contemporary population-based data on use, risk factors and impact of SABA (over)use on asthma exacerbations and mortality are scarce, prompting initiation of the global SABINA (SABA use IN Asthma) programme. Methods: By linking data from Swedish national registries, asthma patients aged 12-45 years with two or more collections of drugs for obstructive lung disease during 2006-2014 were included. SABA overuse was defined as collection of more than two SABA

2020 EvidenceUpdates

5. Asthma mortality in Australia in the 21st century: a case series analysis. Full Text available with Trip Pro

was excluded.Examination of available data in those aged under 70 years identified risk factors associated with asthma death. These included physical barriers (rural and remote location, institutionalised care), psychosocial issues (social disengagement, mental illness, living alone, being unemployed), smoking, drug and alcohol dependence, allergies, respiratory tract infections, inadequate treatment and delay in seeking help.Our study provides a current assessment of death from asthma across Australia. Further (...) reductions in the rate of asthma deaths will require interventions targeted at the personal, practice and policy levels. Asthma-related health literacy needs to be improved especially among those with episodic asthma. Reforms are also needed to address inequity in healthcare delivery to 'reach the unreached'. Our study points to the dangers associated with smoking, drug and alcohol use and the consequences of delay in seeking care among those with asthma.

2013 BMJ open

6. British guideline on the management of asthma

Regular preventer therapy 63 7.3 Initial add-on therapy 70 7.4 Additional controller therapies 72 7.5 Specialist therapies 73 7.6 Deceasing treatment 82 7.7 Specific management issues 82 8 Inhaler devices 85 8.1 Technique and training 85 8.2 ß 2 agonist delivery 85 8.3 Inhaled corticosteroids for stable asthma 86 8.4 Prescribing devices 86 8.5 Use and care of spacers 87 8.6 Environmental impact of metered-dose inhalers 87 9 Management of acute asthma 89 9.1 Lessons from asthma deaths and near-fatal (...) in adolescents 117 11.1 Definitions 117 11.2 Prevalence of asthma in adolescents 117 11.3 Diagnosis and assessment 117 11.4 Risk factors 118 11.5 Comorbidities and modifiable behaviours 119 11.6 Asthma attacks and the risk of hospital admission 120 11.7 Long-term outlook and entry into the workplace 120 11.8 Non-pharmacological management 120 11.9 Pharmacological management 121 11.10 Inhaler devices 121 11.11 Organisation and delivery of care 122 11.12 Patient education and self management 12312 Asthma

2019 SIGN

7. Asthma: diagnosis, monitoring and chronic asthma management

infrequent, short-lived wheeze and normal lung function, consider treatment with SABA reliever therapy alone. 1.6.3 Offer a low dose of an ICS as the first-line maintenance therapy to adults (aged 17 and over) with: symptoms at presentation that clearly indicate the need for maintenance therapy (for example, asthma-related symptoms 3 times a week or more, or causing waking at night) or or asthma that is uncontrolled with a SABA alone. Asthma: diagnosis, monitoring and chronic asthma management (NG80) © (...) to children and young people (aged 5 to 16) with newly diagnosed asthma. 1.7.2 For children and young people (aged 5 to 16) with asthma who have infrequent, short-lived wheeze and normal lung function, consider treatment with SABA reliever therapy alone. 1.7.3 Offer a paediatric low dose of an ICS as the first-line maintenance therapy to children and young people (aged 5 to 16) with: symptoms at presentation that clearly indicate the need for maintenance therapy (for example, asthma-related symptoms 3

2017 National Institute for Health and Clinical Excellence - Clinical Guidelines

8. Impact of Community Health Worker Certification on Workforce and Service Delivery for Asthma and Other Selected Chronic Diseases

. urban area)? 2. Do quality or consistency of care, health outcomes (e.g., asthma control or asthma-related emergency department visits), or patient/family acceptance, trust, and use of community health workers differ among U.S. programs, States, or territories requiring community health worker certification to deliver interventions for asthma and selected other topics or chronic conditions (i.e., diabetes, cardiovascular disease, maternal-child health), compared with those that do not require any (...) to patients’ asthma-related outcomes, and/or outcomes of other chronic diseases? Does it matter to you if the CHW you work with has been certified? Why? Why not? What is the infrastructure needed to support CHW certification? What should the components of CHW certification be? Should there be maintenance or re-certification? How do you attribute the work of CHWs to health outcomes? How would you measure the impact of a CHW? Should CHWs’ hiring and promotion require certification? How might certification

2020 Effective Health Care Program (AHRQ)

9. Characteristics of Existing Asthma Self-Management Education Packages

of professionals play a greater or different role in delivering AS-ME? How does this vary by patient population? 5. How should packages be accessed by patients? How might online/mobile technology be incorporated into design/delivery of AS-ME? 6. What are the most important clinical and psychosocial goals for patients who engage in AS-ME? How should outcomes be assessed? 7. How can/should packages address population differences such as age, literacy, social/cultural/economic factors, and high-risk patients? 8 (...) Intervention Asthma self-management education (AS-ME) packages with: • interactive component • description of methodology for use or implementation • available in the United States Comparator No intervention Control Standard of care Other AS-ME package(s) Outcomes Reports at least one outcome of interest listed under Guiding Question 3: • Asthma control • Asthma-related healthcare utilization • Asthma-related medication adherence • Asthma-related quality of life • Ease of use • Acceptability • Patient

2020 Effective Health Care Program (AHRQ)

10. Tiotropium (Spiriva Respimat) add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma

analysis assumes no asthma-related mortality occurs; age-specific mortality is assumed based on UK life tables. Incorporation of mortality associated with exacerbations is explored in a scenario analysis, using a published database study of asthma mortality following hospital admission 16 . All patients enter the model in the uncontrolled health state. Probabilities of transitioning to other asthma control states are derived from the pooled phase III study populations with complete ACQ-7 score data (...) %. Tiotropium was dominant (more effective/less costly) in 2.5% of the simulations, was more effective and more costly in 96.2% of simulations, and tiotropium was dominated in 1.3% of simulations. Scenario analyses explored incorporation of mortality risk in patients hospitalised with severe exacerbations, a 20% reduction in selected utility values, the use of transition probabilities derived from weeks 47–48 of the clinical studies for extrapolation of long-term effects, and incorporation of work

2018 All Wales Medicines Strategy Group

11. Performance of the Belgian health system

at the time of death, it could have been avoided by public health policies focusing on wider determinants of public health, such as lifestyles, socioeconomic status and environmental factors (e.g. deaths from road accident, lung cancer, alcohol-related diseases). Concerning mortality regarded as potentially amenable through the health care system, Belgium ranks rather well within EU-15 countries for men and average for women. This mortality is decreasing over time, and is higher in Brussels and Wallonia (...) of care. 24 Belgium is situated around the EU-15 average for both indicators, but this is not very informative, as differences between countries can be due to many other factors than to effectiveness of care, such as difference in prevalence of the disease, in accessibility of care or in methodology for measuring the indicator. Asthma-related admissions show a decreasing trend in the early 2000, which was also the case in other EU-15 countries, but stabilized since 2008. Rates are similar in Wallonia

2019 Belgian Health Care Knowledge Centre

12. ESC/ESH Management of Arterial Hypertension Full Text available with Trip Pro

. Detailed information on CV risk assessment is available. Factors influencing CV risk factors in patients with hypertension are shown in Table . Hypertensive patients with documented CVD, including asymptomatic atheromatous disease on imaging, type 1 or type 2 diabetes, very high levels of individual risk factors (including grade 3 hypertension), or chronic kidney disease (CKD; stages 3 − 5), are automatically considered to be at very high (i.e. ≥10% CVD mortality) or high (i.e. 5 − 10% CVD mortality (...) Substantial progress has been made in understanding the epidemiology, pathophysiology, and risk associated with hypertension, and a wealth of evidence exists to demonstrate that lowering blood pressure (BP) can substantially reduce premature morbidity and mortality. A number of proven, highly effective, and well-tolerated lifestyle and drug treatment strategies can achieve this reduction in BP. Despite this, BP control rates remain poor worldwide and are far from satisfactory across Europe. Consequently

2018 European Society of Cardiology

13. Supporting Parents in Making Informed Decisions in Relation to their Children?s Health Needs

be interpreted with caution. McMaster Health Forum) Systematic review To assess the benefits and potential harms of shared decision-making for children and adults with asthma (11) This review included four studies that examined the effects of shared decision-making on asthma-related quality of life, patient satisfaction with care, medication adherence, exacerbations of asthma, asthma control, and unwanted effects. Three studies reported asthma-related quality of life as an outcome. One study involving adults (...) children, patient/parent satisfaction with the performance of pediatricians was greater in the shared decision-making group as compared to the control group. Medication adherence was higher in the shared decision-making group in two studies – one involving adults and one involving children. Three studies assessed exacerbations of asthma as an outcome. Of these three, one study found that asthma-related visit rates were lower in the shared decision-making group than in the usual care group. However

2018 McMaster Health Forum

14. Mepolizumab for treating severe refractory eosinophilic asthma

). Page 15 of 29Age-adjusted mortality r Age-adjusted mortality rates ates 4.15 The committee discussed the mortality rates in the company's model. The committee was aware that mortality rates affected the cost effectiveness of mepolizumab. It also noted that the company used Watson et al. (2007) for data on 'mortality after an exacerbation resulting in hospitalisation' , and that this resulted in a constant rate of asthma-related mortality for people aged 45 years and over. The committee agreed (...) with the ERG that stratifying mortality into narrower age bands, including having a different rate for 65 years and above, gave a more plausible measure of asthma-related mortality. The committee noted the company used the ERG's preferred approach to estimate the asthma- related mortality in its response to the second appraisal consultation document and concluded that this was appropriate. Dur Duration of treatment ation of treatment 4.16 The committee discussed the duration of treatment in the company's

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

15. Comparative Effectiveness of Analgesics To Reduce Acute Pain in the Prehospital Setting

investigators screened abstracts, reviewed full-text files, abstracted data, and assessed study-level risk of bias. We performed meta-analyses when appropriate and graded the strength of evidence (SOE) upon which conclusions were made for a priori determined comparisons and outcomes. We defined the following as clinically important differences: 2 points on a 0 to 10 pain scale; time to analgesia of 5 minutes; 10-percent absolute risk difference for any adverse event; and 5-percent absolute risk difference (...) adverse events than ketamine (low SOE), primarily administered intranasally. Opioids cause less dizziness than ketamine (low SOE) but may increase the risk of respiratory depression compared with ketamine (low SOE), primarily administered IV. Opioids cause more dizziness (moderate SOE) and may cause more adverse events than APAP (low SOE), both administered IV, but we found no evidence of a clinically important difference in hypotension (low SOE). Opioids may cause more adverse events and more

2019 Effective Health Care Program (AHRQ)

16. Registries for Evaluating Patient Outcomes: A User's Guide

Data 21 Strengths of PGHD 22 Limitations of PGHD 23 Genomic Data 25 Radiological Image Data 26 Clinical Data Warehouses 27 Health Information Exchanges 30 Conclusion 31 References for Chapter 2 32 Chapter 3. Data Standards 37 Contents v Authors (alphabetical) 37 Introduction 37 Vocabulary and Terminology Standards 38 Common Data Elements 39 Standardized Outcome Measures 39 Development of the OMF 41 Structure of the OMF 43 Use of the OMF To Support Measure Harmonization 44 Survival Measures 46 (...) -Generated Data 59 Sample Use Cases and Architecture of EHR-Based Registries 60 Contents vi EHR-Integrated Registries To Support Clinical Care 62 EHR-Linked Registries Designed for Research 64 EHR-Linked Public Health Registries 66 Technical Issues and Operational Challenges of EHR-Based Registries 67 Identifying Eligible Patients 67 Data Quality 68 Unstructured Data 69 Interoperability 70 EHR Infrastructure and Deployment 71 Data Access, Privacy, and Use 71 Human Resources 71 Other Factors 72

2019 Effective Health Care Program (AHRQ)

17. BTS/SIGN British Guideline on the Management of Asthma

Regular preventer therapy 63 7.3 Initial add-on therapy 70 7.4 Additional controller therapies 72 7.5 Specialist therapies 73 7.6 Deceasing treatment 82 7.7 Specific management issues 82 8 Inhaler devices 85 8.1 Technique and training 85 8.2 ß 2 agonist delivery 85 8.3 Inhaled corticosteroids for stable asthma 86 8.4 Prescribing devices 86 8.5 Use and care of spacers 87 8.6 Environmental impact of metered-dose inhalers 87 9 Management of acute asthma 89 9.1 Lessons from asthma deaths and near-fatal (...) in adolescents 117 11.1 Definitions 117 11.2 Prevalence of asthma in adolescents 117 11.3 Diagnosis and assessment 117 11.4 Risk factors 118 11.5 Comorbidities and modifiable behaviours 119 11.6 Asthma attacks and the risk of hospital admission 120 11.7 Long-term outlook and entry into the workplace 120 11.8 Non-pharmacological management 120 11.9 Pharmacological management 121 11.10 Inhaler devices 121 11.11 Organisation and delivery of care 122 11.12 Patient education and self management 12312 Asthma

2019 British Thoracic Society

18. Recognition and management of severe asthma - Position Statement

, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada; m Department of Family Medicine, McGill University, Montreal, Quebec, Canada ABSTRACT RATIONALE: While severe asthma affects approximately 5% of all individuals with asthma, this small minority of individuals accounts for a large proportion of the asthma-related costs. Greater understanding of the pathophysiology of asthma combined with the emergence of novel biologic therapies for severe asthma supported the need (...) a substantial burden on individuals, and the health care system. Even though asthma mortality has declined and is now infrequent in Canada, 2 a recent review of asthma deaths in the United Kingdom has shown these events are often avoidable. 3 In addition there are accumulating data to suggest that uncontrolled asthma is highly prevalent in Can- ada. 4 While most uncontrolled asthma cases can be addressed with self-management education and pharmacologic strategies outlinedinrecentevidence-basedguidelines

2018 Canadian Thoracic Society

19. Mindfulness?based stress reduction (MBSR) for improving health, quality of life and social functioning in adults: a systematic review and meta?analysis Full Text available with Trip Pro

hope scale, AGN Tot Com= Affective Go No Go task total commissions, Albuminuria, Analgesic medic= Analgesic medication, Anger Rum S=Anger Rumination Scale, Anx Sens I=Anxiety Sensitivity Index, Anx aboutspeech= Anxiety about speech, AQOL= Asthma related quality of life, Area UT Cseverity= Area under the curve severity, ARM=Affect Regulation Measure, ART side effects= Anti‐retroviral therapy side effects (bother and severity), ASI=Addiction Severity Index, AUC= Area under the curve, Aud/SAl (BA (...) Share a link Share on ; ). Likewise, there is mounting evidence that stress caused by traumatic life events increases the risk for chronic somatic and psychological problems that affect health and quality of life ( ); adverse childhood experiences being especially harmful ( ; ). Demands may be external, but stress is also generated from within. The stressors can be actual or imagined. How we handle situations, persons and emotions ‐ becoming stressed or keeping calm ‐ is therefore central to staying

2017 Campbell Collaboration

20. Effectiveness of Indoor Allergen Reduction in Management of Asthma

emergency department visits and 439,000 hospitalizations. While the severity of disease varies between patients and over time in the same patient, asthma can be fatal, accounting for approximately 1 death per 100,000 Americans. 5 Effectiveness of Indoor Inhalant Allergen Reduction Control of environmental factors that may contribute to asthma is one of the four components of asthma management. Many common indoor inhalant allergens have been associated with increased risk of asthma exacerbations (...) and multicomponent interventions does not address many other important outcomes, including asthma-related health care utilization, pulmonary physiology, and asthma-related quality of life. iii This report is based on research conducted by the ECRI Institute–Penn Medicine Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2015-00005-I). The National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI

2018 Effective Health Care Program (AHRQ)

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>